Status:
UNKNOWN
Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker
Lead Sponsor:
Slovak Academy of Sciences
Conditions:
Hypertension
Eligibility:
MALE
25-50 years
Phase:
NA
Brief Summary
It is supposed that the significant metabolic effects (improvement of insulin sensitivity) of hypertension therapy with renin-angiotensin system (RAS) blockers in humans are mediated mainly via change...
Detailed Description
Arterial hypertension is nowadays considered a metabolic disease, due to its occurrence together with other risk factors of atherosclerosis like obesity, dyslipidemia, insulin resistance, impaired glu...
Eligibility Criteria
Inclusion
- essential hypertension
- ACE inhibitors
Exclusion
- diabetes mellitus
- endocrinopathies
- no smokers
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2012
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT01444833
Start Date
October 1 2008
End Date
December 1 2012
Last Update
October 3 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Experimental Endocrinology, SAS
Bratislava, Slovakia, 833 06